Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7436627 | 0.85 | CYP2A6 (0.47) | CYP2A6PGRNOS3NOS1NOS2 | |
| SCHEMBL6014124 | 0.78 | CYP2A6 (0.60) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12356972 | 0.78 | CYP2A6 (0.49) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL28129144 | 0.77 | CYP2A6 (0.52) | CYP2A6DYRK1ACHRM2CHRM4CHRM5 | |
| SCHEMBL28128673 | 0.77 | CYP2A6 (0.52) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL18936170 | 0.77 | CYP2A6 (0.52) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14677379 | 0.77 | CYP2A6 (0.52) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL13079657 | 0.77 | HRH3 (0.52) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11839904 | 0.76 | MAOB (0.56) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5032875 | 0.76 | HRH3 (0.51) | CYP2A6CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| EP-2922137-B1 | PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, DYE-ADSORBED ELECTRODE, AND METHOD FOR MANUFACTURING DYE-SENSITIZED SOLAR CELL | FUJIFILM CORP (JP) | 2019-04-03 | — | — | EP | disclosed |
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| CN-106478500-A | Carboxylic acid-substituted（Miscellaneous）Aromatic ring analog derivative and its production and use | 广东东阳光药业有限公司 | 2017-03-08 | — | — | CN | disclosed |
| EP-2344484-B1 | S1P RECEPTORS MODULATORS AND USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2016-06-08 | — | — | EP | disclosed |
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD. (AU) | 2016-02-11 | — | — | US | disclosed |
| US-9193716-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2015-11-24 | — | — | US | disclosed |
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| WO-2010043000-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2000078724-A2 | IMIDAZOLINDERIVATIVES THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-0073663-B1 | THROMBOXANE SYNTHETASE INHIBITORS, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pfizer Limited (GB) | 1986-06-18 | — | — | EP | disclosed |
| US-4590200-A | NON-INHIBITION OF PROSTACYCLIN SYNTHETASE OR CYCLO-OXYGENASE | PFIZER INC. (US) | 1986-05-20 | — | — | US | disclosed |
| US-4496572-A | Benzo-fused thromboxane synthetase inhibitors | PFIZER INC. (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0073663-A2 | Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them | Pfizer Limited (GB) | 1983-03-09 | — | — | EP | disclosed |
| US-4341792-A | ANTIDIABETIC AND CARDIOTONIC AGENTS | PFIZER INC. (US) | 1982-07-27 | — | — | US | disclosed |
| EP-0026593-A1 | Bicyclic keto- and amino- acids, esters and amides and pharmaceutical compositions thereof | Pfizer Limited (GB) | 1981-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | S1PR1, S1PR5, S1PR2 | CYP2A6 3414/4885DYRK1A 1754/4885CHRM2 1333/4885 |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | GCGR, GLP1R, GPR119 | CYP2A6 1336/4885DYRK1A 2876/4885CHRM2 435/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | CYP2A6 451/4885DYRK1A 534/4885CHRM2 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.